ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1582944
Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study
Provisionally accepted
- 1Department of Hematology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
- 2Clinical Research Ward of Cancer Center, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: CD19 Chimeric Antigen Receptor T-cell therapy (CART) represents a groundbreaking approach in the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). However, a subset of patients fails to achieve optimal outcomes with CD19-targeted CAR T-cells alone. To address these limitations, the development of multi-targeted CART therapies has become a focal point of innovative research. This study aims to compare the therapeutic efficacy and adverse events of dual-target versus single-target CART therapies in R/R DLBCL patients through a single-centre retrospective analysis.Methods: We included 70 patients with R/R DLBCL treated at Shanghai Tongji Hospital between January 1, 2019, and December 31, 2021. Among them, 20 patients received dual-target (CD19/20) CART, while 50 underwent CD19 CART.Results: The CD19/20 CART group demonstrated significantly superior three-month efficacy to the CD19 CAR T-cell group, with a notably higher complete response (CR) rate. The median progression-free survival (PFS) and overall survival (OS) were 28.6 and 31.8 months longer in the Bi-CART group compared to the CD19 CAR T-cell group. However, the two groups had no significant differences in overall PFS, duration of response (DOR), or OS. The CD19/20 CART group exhibited a higher incidence of cytokine release syndrome (CRS), hematological toxicity, infections, and secondary primary tumors.Conclusion: This study highlights the superior efficacy of dual-target CAR T-cell therapy in managing R/R DLBCL patients. The dual-target therapy significantly extended median survival compared to CD19 single-target CAR T-cell therapy. However, the enhanced therapeutic benefits were accompanied by a higher incidence of adverse effects.
Keywords: car-t, Lymphoma, Dual-target, CD19, CD19/20
Received: 25 Feb 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Xue, Liu, Li, Lu, Zhou, Ye, Lu, Luo, Liang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiu Luo, Department of Hematology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
Aibin Liang, Department of Hematology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
Ping Li, Department of Hematology, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.